Last reviewed: July 7, 2026
Last updated: July 7, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Two injectable medications now dominate the precision weight-loss landscape: tirzepatide, a dual GLP-1/GIP receptor agonist, and semaglutide, a selective GLP-1 agonist. Clinical trials show tirzepatide produces greater average weight reduction—up to 22% body weight loss in some cohorts—compared to semaglutide's 17% average, though individual results vary significantly based on genetics, lifestyle, and metabolic factors. PlexusDx offers both as compounded options, with genetic testing available to identify which therapy may work best for your unique peptide pathways.
How Tirzepatide and Semaglutide Work Differently
Semaglutide activates only the GLP-1 receptor, mimicking a natural hormone that slows stomach emptying, reduces appetite, and improves insulin secretion. This single-pathway approach has been used safely for over a decade and remains highly effective for many patients seeking steady, predictable weight loss and blood sugar improvement.
Tirzepatide engages both GLP-1 and GIP receptors simultaneously—a dual-action mechanism that amplifies satiety signaling, enhances glucose-dependent insulin release, and increases energy expenditure in fat tissue. This two-pathway activation may explain why tirzepatide trials consistently show larger weight reductions and more pronounced improvements in insulin resistance markers.
Clinical Trial Outcomes: Weight Loss and Metabolic Benefits
The SUSTAIN series (semaglutide trials) demonstrated sustained weight loss of 10–17% over 68 weeks, with strong cardiovascular safety data and significant reductions in HbA1c levels in patients with type 2 diabetes. These results established semaglutide as a gold-standard therapy for long-term glycemic and weight management.
The SURMOUNT trials (tirzepatide) reported average weight losses of 20–22% at the highest maintenance doses, with similar cardiovascular protections and more pronounced improvements in triglycerides and liver fat content. The dual-receptor approach appears particularly effective for patients with insulin resistance or metabolic dysfunction, though individual response depends heavily on genetic variation in GLP1R and GIPR expression.
How Your Genetics Relate to GLP-1 Pathways
Not all patients respond equally to either medication, and genetic variation explains much of this difference. Key variants in the GLP1R gene (rs6923761), GIPR gene (rs1800437), and FTO gene (rs9939609) influence receptor sensitivity, baseline appetite set-point, and fat-mass distribution—all factors that shape how aggressively each therapy works in your body.
The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, and GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Tolerability, Side Effects, and Treatment Adherence
Both medications share a common side-effect profile: nausea (especially in weeks 1–4), constipation, occasional vomiting, and appetite suppression that can become excessive. Semaglutide's narrower mechanism sometimes results in fewer overall adverse events, while tirzepatide's dual action occasionally produces more gastrointestinal upset during dose escalation—though this typically resolves as your body adapts.
Long-term adherence differs based on individual tolerance and metabolic response. Patients experiencing rapid early weight loss on tirzepatide often report higher motivation to continue despite initial nausea, whereas semaglutide's gentler titration curve appeals to those seeking a slower, more predictable adjustment period. PlexusDx dosing is flat-rate regardless of strength, so there is no financial penalty for finding your optimal dose; your dose may need to go up, but your price won't.
Cost, Access, and Personalized Treatment at PlexusDx
PlexusDx Compounded Tirzepatide Injection starts at $289/mo (or $249/mo on the 6-month plan) across all commitment tiers, while Compounded Semaglutide Injection begins at $189/mo (or $149/mo on the 6-month plan). Both are manufactured by licensed 503A compounding pharmacies, available nationwide without insurance or membership fees, and eligible for HSA/FSA accounts—making precision GLP-1 therapy accessible regardless of employment status or insurance coverage.
If you're uncertain which medication suits your metabolism best, PlexusDx recommends starting with either option and adding the Precision Peptide Genetic Test in month two. This $99 add-on provides a personalized roadmap of your GLP1R, GIPR, FTO, and MC4R genotypes, helping your PlexusDx provider adjust your therapy or suggest a switch if you're not seeing expected results. For patients wanting both mechanisms simultaneously, PlexusDx also offers GLP-Squared Injection (dual semaglutide + tirzepatide compound) starting at $289/mo (or $249/mo on the 3-month plan).
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Which medication causes more weight loss: tirzepatide or semaglutide?
Clinical trials show tirzepatide averages 20–22% body weight loss compared to semaglutide's 10–17% range. However, individual results vary significantly based on genetics, baseline metabolism, and adherence. PlexusDx Precision Peptide Genetic Testing can reveal whether your GLP1R and GIPR genotypes favor a faster response to tirzepatide's dual-action approach.
Is tirzepatide FDA-approved for weight loss if I don't have diabetes?
Yes—tirzepatide (brand name Zepbound) received FDA approval for weight management in non-diabetic adults in November 2023. PlexusDx offers compounded tirzepatide injection from licensed 503A pharmacies, which provides the same active pharmaceutical ingredient without requiring an insurance approval or prior-authorization delay.
Can I switch from semaglutide to tirzepatide if I'm not losing weight?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
What are the most common side effects, and how long do they last?
Nausea, constipation, and reduced appetite are typical in weeks 1–4 as your body adapts. Most side effects subside within 2–4 weeks; staying hydrated, eating protein-rich meals, and increasing fiber gradually helps. If nausea persists beyond 6 weeks or interferes with daily function, notify your PlexusDx provider to discuss dose adjustment or alternative timing strategies.
How does genetic testing help me choose between these medications?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Does PlexusDx accept insurance, or is it cash-only?
PlexusDx serves all 50 states with no insurance requirement and no membership fees. Semaglutide Injection starts at $189/mo (or $149/mo on the 6-month plan) and Tirzepatide Injection at $289/mo (or $249/mo on the 6-month plan)—flat pricing regardless of dose. Both are HSA/FSA eligible, and many patients find out-of-pocket costs lower than insurance copays or deductibles for branded equivalents.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Ozempic Pen Not Working? A Practical Guide to Troubleshooting Your Device
Can You Drink Alcohol on Wegovy? Understanding the Interactions